We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · June 08, 2021

Novel Risk Scoring System for mRCC Patients Treated With Cabozantinib

Cancer treatment and research communications

 

Additional Info

Cancer treatment and research communications
Novel Risk Scoring System for Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib
Cancer Treat Res Commun 2021 May 09;28(xx)100393, DJ Martini, MR Kline, Y Liu, JM Shabto, BC Carthon, GA Russler, L Yantorni, EE Hitron, S Caulfield, JM Goldman, WB Harris, O Kucuk, VA Master, MA Bilen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading